GlassScriptPhysician profile
William S Knight
NPI 1245314475
$4,031.01
in general payments reported to CMS, 2019-2025
24 companies · $718 in 2025
The $718 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $137 · 2022: $827 · 2023: $1,026 · 2024: $531 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.08 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $780.78 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $562.47 | 2019-2023 | Veozah, Myrbetriq |
| Novo Nordisk INC | $447.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $304.57 | 2019-2025 | |
| Abbvie INC. | $296.90 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $261.44 | 2023-2025 | Acthar |
| Pfizer INC. | $261.22 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $260.71 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.24 | 2019-2024 | Synjardy, Ofev |
| Amgen INC. | $174.58 | 2019-2023 | Otezla, Repatha, Evenity |
| Sumitomo Pharma America, INC. | $85.75 | 2025 | Gemtesa |
| Exact Sciences Corporation | $61.06 | 2024-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $38.08 | 2022-2023 | Eliquis |
| Bausch Health US, LLC | $36.77 | 2025 | Aplenzin |
| Merck Sharp & Dohme LLC | $31.54 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29.74 | 2019 | |
| Allergan, INC. | $27.08 | 2019 | |
| Eisai INC. | $24.34 | 2024 | |
| Sanofi Pasteur INC. | $22.17 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.31 | 2019 | |
| Amarin Pharma, INC. | $19.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.96 | 2019 | |
| Daiichi Sankyo INC. | $13.99 | 2019 | |
| Circassia INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.